TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - ELI LILLY & CO TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - ELI LILLY & CO Share Price
Certificat
DE000SW14558
| Delayed Deutsche Boerse AG 01:15:54 22/05/2024 am IST | ||
| 17.4 EUR | -10.03% |
|
| Current month | -13.17% | ||
| 1 month | -30.59% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 21/24/21 | 17.4 | -10.03% |
| 20/24/20 | 19.34 | -5.38% |
| 17/24/17 | 20.44 | +1.14% |
| 16/24/16 | 20.21 | +4.72% |
| 15/24/15 | 19.3 | -9.18% |
Delayed Quote Deutsche Boerse AG
Last update May 22, 2024 at 01:15 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SW1455 |
| ISIN | DE000SW14558 |
| Date issued | 10/08/2023 |
| Strike | 990.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 42.9 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 45.19 € |
|---|---|
| Lowest since issue | 17.05 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
803.2
USD
Average target price
850.4
USD
Spread / Average Target
+5.88%
- Stock Market
- Certificates
- Certificat